THURSDAY, Jan. 30, 2025 -- The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA)...

FRIDAY, Feb. 7, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of...

Several years ago, a little-known drug named Ozempic – previously used only to treat diabetes – emerged as a promising new drug for weight...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity,...

FRIDAY, Feb. 7, 2025 -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity,...

A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the risk of dementia in...

WEDNESDAY, Feb. 12, 2025 -- Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with...

Datopotamab deruxtecan (Dato─DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these...

The promise of help with weight loss is always alluring. But what if that solution comes with a few hidden risks?In South Africa, where obesity rates...